Personalizing blood thinners after carotid stenting could prevent heart attacks and strokes

NCT ID NCT05566301

Recruiting now Disease control Sponsor: IRCCS Policlinico S. Donato Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study looks at people with narrowed carotid arteries who are getting a stent. Some people do not respond well to the common blood thinner clopidogrel. The study compares giving these 'non-responders' a different drug, ticagrelor, versus continuing clopidogrel in those who respond. Researchers will track deaths, major heart events, and bleeding for up to three months after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Clopidogrel and Ticagrelor
What this could lead to: If successful, this could help doctors choose the right antiplatelet drug for each patient, potentially reducing heart attacks, strokes, and bleeding after carotid stenting.
What could go wrong: This is an observational study, not a randomized trial, so results may show associations but not prove cause. The findings may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAROTID STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carotid stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAROTID STENOSIS CLOPIDOGREL, POOR METABOLISM OF

Contacts and locations

Locations

IRCCS Policlinico San Donato
RECRUITING

San Donato Milanese, Milan, 20097, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.